(Q38009878)

https://github.com/jmillanacosta/retractable/blob/e28dcac33244e89948fe17fb65f09b59e2ed804d/data/PMIDS_DOIS.csv

26 August 2017

1 reference

title

Gantenerumab for the treatment of Alzheimer's disease (English)

1 reference

26 August 2017

0 references

3

Bruno Vellas

1 reference

26 August 2017

Julien Delrieu

1

1 reference

26 August 2017

Pierre Jean Ousset

series ordinal

2

1 reference

26 August 2017

language of work or name

English

0 references

publication date

15 May 2012

1 reference

Expert Opinion on Biological Therapy

26 August 2017

published in

1 reference

26 August 2017

volume

12

1 reference

26 August 2017

issue

8

1 reference

26 August 2017

page(s)

1077-1086

1 reference

Hypothetical model of dynamic biomarkers of the Alzheimer's pathological cascade

26 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.688022

Visualization of A beta 42(43) and A beta 40 in senile plaques with end-specific A beta monoclonals: evidence that an initially deposited species is A beta 42(43).

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.688022

Soluble Aβ oligomer production and toxicity

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.688022

The second-generation active Aβ immunotherapy CAD106 reduces amyloid accumulation in APP transgenic mice while minimizing potential side effects.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.688022

Immunization with amyloid-beta attenuates Alzheimer-disease-like pathology in the PDAPP mouse

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.688022

A beta peptide immunization reduces behavioural impairment and plaques in a model of Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.688022

Imaging of amyloid-beta deposits in brains of living mice permits direct observation of clearance of plaques with immunotherapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.688022

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.688022

Solanezumab for Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.688022

Antibody-based therapy in Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.688022

A phase 2 multiple ascending dose trial of bapineuzumab in mild to moderate Alzheimer disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.688022

11C-PiB PET assessment of change in fibrillar amyloid-beta load in patients with Alzheimer's disease treated with bapineuzumab: a phase 2, double-blind, placebo-controlled, ascending-dose study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.688022

Safety and changes in plasma and cerebrospinal fluid amyloid beta after a single administration of an amyloid beta monoclonal antibody in subjects with Alzheimer disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.688022

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.688022

Consequence of Abeta immunization on the vasculature of human Alzheimer's disease brain.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.688022

Immunotherapy, vascular pathology, and microhemorrhages in transgenic mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.688022

Immunotherapy reduces vascular amyloid-beta in PDAPP mice.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.688022

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.688022

Mechanism of amyloid removal in patients with Alzheimer disease treated with gantenerumab.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.688022

Rapid microglial response around amyloid pathology after systemic anti-Abeta antibody administration in PDAPP mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.688022

Subacute meningoencephalitis in a subset of patients with AD after Abeta42 immunization

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.688022

Clinical effects of Abeta immunization (AN1792) in patients with AD in an interrupted trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.688022

Pre-dementia Alzheimer's trials: overview

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.688022

Seeing with new eyes: finding a path to early intervention trials in Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.688022

Redox-active iron mediates amyloid-beta toxicity

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.688022

Lipid peroxidation and 4-hydroxy-2-nonenal formation by copper ion bound to amyloid-beta peptide

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.688022

Three histidine residues of amyloid-beta peptide control the redox activity of copper and iron

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.688022

Alzheimer disease pathology as a host response

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.688022

Amyloid beta: the alternate hypothesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.688022

Neuropathology of Alzheimer disease: pathognomonic but not pathogenic

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.688022

Therapeutic antibodies for human diseases at the dawn of the twenty-first century

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.688022

A single ascending dose study of bapineuzumab in patients with Alzheimer disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.688022

Comparison of pharmacokinetics, pharmacodynamics, safety, and tolerability of the amyloid β monoclonal antibody solanezumab in Japanese and white patients with mild to moderate alzheimer disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.688022

Exacerbation of cerebral amyloid angiopathy-associated microhemorrhage in amyloid precursor protein transgenic mice by immunotherapy is dependent on antibody recognition of deposited forms of amyloid beta.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.688022

Amyloid-beta in Alzheimer Disease: The Null versus the Alternate Hypotheses

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.688022

Gantenerumab: a novel human anti-Aβ antibody demonstrates sustained cerebral amyloid-β binding and elicits cell-mediated removal of human amyloid-β

21 January 2018

1 reference

30 December 2023

https://opencitations.net/index/api/v1/references/10.1517/14712598.2012.688022

[Vaccination therapy for Alzheimer's disease]

1 reference

30 December 2023

https://opencitations.net/index/api/v1/references/10.1517/14712598.2012.688022

Immunotherapy for Alzheimer's disease

1 reference

30 December 2023

https://opencitations.net/index/api/v1/references/10.1517/14712598.2012.688022

Has the amyloid cascade hypothesis for Alzheimer's disease been proved?

1 reference

30 December 2023

https://opencitations.net/index/api/v1/references/10.1517/14712598.2012.688022

Identifiers

DOI

10.1517/14712598.2012.688022

1 reference

release_iijxadqme5g7lovxfe6rdv4eka

26 August 2017

Fatcat ID

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/iijxadqme5g7lovxfe6rdv4eka

mapped directly with Wikidata item

24 November 2022

based on heuristic

1 reference